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Exosomes are small membrane vesicles secreted into
the extracellular compartment by exocytosis. Tumor
exosomes may be involved in the sampling of anti-
gens to antigen presenting cells or as decoys allowing
the tumor to escape immune-directed destruction.
The proteins present in exosomes secreted by tumor
cells have been poorly defined. This study describes
the protein composition of mesothelioma cell-de-
rived exosomes in more detail. After electrophoresis
of exosome preparations, matrix-assisted laser de-
sorption ionization time-of-flight (MALDI-TOF) was
used to characterize the protein spots. MHC class I
was found to be present together with the heat shock
proteins HSC70 and HSP90. In addition, we found
annexins and PV-1, proteins involved in membrane
transport and function. Cytoskeleton proteins and
their associated proteins ezrin, moesin, actinin-4,
desmoplakin, and fascin were also detected. Besides
the molecular motor kinesin-like protein, many en-
zymes were detected revealing the cytoplasmic orien-
tation of exosomes. Most interesting was the detec-
tion of developmental endothelial locus-1 (DEL-1),
which can act as a strong angiogenic factor and can
increase the vascular development in the neighbor-
hood of the tumor. In conclusion, mesothelioma cells
release exosomes that express a discrete set of pro-
teins involved in antigen presentation, signal trans-
duction, migration, and adhesion. Exosomes may
play an important role in the interaction between
tumor cells and their environment. (Am J Pathol
2004, 164:1807–1815)
Like most cells of hematopoietic origin, tumor cells se-
crete exosome-like vesicles. These subcellular mem-
brane vesicles from endosomal origin are secreted on
fusion of multi-vesicular bodies with the plasma mem-
brane.1,2 As a consequence, exosomes have a “cellular”
membrane orientation with a limited range of proteins
derived from the cytosol, endocytic compartment mem-
branes, and plasma membranes.3 They are 60 to 110 nm
in diameter, and may be involved in the communication
between cells. Exosomes from a murine dendritic cell
(DC) line D1 are best characterized for protein composi-
tion.4,5 Proteins expressed on these DC-derived exo-
somes are involved in the regulation of basic processes
like signal transduction, adhesion, activation, and migra-
tion. In addition, MHC-I and MHC-II, proteins normally
involved in antigen presentation, are expressed on DC-
derived exosomes.
Although DC-derived exosomes are able to activate
cytotoxic T cells and to elicit potent anti-tumor immune
responses,4 the function of tumor cell-derived exosomes
is unknown. They may serve as decoys by allowing the
tumor to escape immune-directed destruction or for sam-
pling antigens to DC. Wolfers et al6 demonstrated that
tumor-derived exosomes are capable of transferring tu-
mor antigens to DC, inducing a CD8 T-cell-dependent
cross-immunization of tumor-bearing mice. These exo-
somes seem to concentrate a set of whole native shared
tumor antigens opening the possibility that exosomes
could be used as a source of antigen in vaccination
protocols.6,7 Proteomics offers the possibility to under-
stand more about human tumor-derived exosomes and
these organelles may, like DC-derived exosomes, give
new perspectives to improve the diagnosis and therapy
of cancer patients.8–10
Malignant mesothelioma (MM) is a tumor of mesoder-
mally derived tissue lining the coelomic cavities with no
satisfactory curative treatment.11 This tumor was chosen
as a model system to study the characteristics of tumor-
derived exosomes because only a small amount of data
are available on tumor antigens in this tumor.
Matrix-assisted laser desorption ionization time-of-
flight (MALDI-TOF) mass spectrometry was used for the
proteomic analysis of exosomes derived from well-char-
acterized mesothelioma cell lines. The focus of this article
will be on the proteins present in tumor exosomes.
Supported by “Stichting Asbestkanker Rotterdam.”
Accepted for publication January 6, 2004.
Address reprint requests to Joost P.J.J. Hegmans, Erasmus MC, De-
partment of Pulmonary Medicine, P.O. Box 1738; 3000 DR, Rotterdam,
The Netherlands. E-mail: j.hegmans@erasmusmc.nl.
American Journal of Pathology, Vol. 164, No. 5, May 2004
Copyright © American Society for Investigative Pathology
1807
Materials and Methods
Establishment of Human Mesothelioma Cell Lines
Mesothelioma cell lines have been derived from pleural
effusions or primary solid tumor biopsy material. After
informed consent, patient material was collected under
sterile conditions and transported immediately to the lab-
oratory. Solid tissue was minced into small pieces with
sterile scissors and gently pressed through a 100-m
mesh cell strainer (Falcon/Becton Dickinson Labware,
Franklin Lakes, NJ) with a syringe piston. Dispersed cells
and clumps were washed through gauze with HBBS
(GIBCO/Invitrogen, Breda, The Netherlands), and the
suspension was transferred to a second finer (40-m
mesh) gauze (Falcon/Becton Dickinson Labware). Sus-
pension was centrifuged at 400  g for 15 minutes at
room temperature (RT) and cells placed into culture
flasks (Falcon/Becton Dickinson Labware). Pleural effu-
sions were centrifuged 400  g for 15 minutes and cells
were placed into culture flasks. Cells were cultured at
37°C in RPMI 1640 medium containing 25 mmol/L
HEPES, Glutamax, 50 g/ml gentamicin, and 10% (v/v)
fetal bovine serum (FBS) (all obtained from GIBCO/In-
vitrogen) in a humidified atmosphere of 5% CO2, in air.
Media were changed once or twice a week and when
flasks were confluent, then cells were passaged to a new
flask by treatment with 0.05% trypsin and 0.53 mmol/L
EDTA in phosphate-buffered saline (PBS, all from
GIBCO/Invitrogen). Two cell lines (PMR-MM7 and PMR-
MM8) were extensively characterized and kept in long-
term cell culture (50 passages, 6 months of culturing)
while using for exosome isolation.
Characterization of Cell Lines
Cellular DNA Content
Cell lines were characterized for cellular DNA content
by propidium iodide. In short, cells were trypsinized and
washed twice in 0.1% (w/v) glucose (Sigma-Aldrich Che-
mie BV, Zwijndrecht, The Netherlands) in PBS. A pellet
containing 1  106 cells was resuspended by slowly
adding 1 ml of ice-cold 70% ethanol under vigorous
vortexing. The suspension was fixed overnight at 4°C and
the next day the pellet was resuspended in 1 ml 0.1%
(w/v) glucose in PBS supplemented with 50 g/ml pro-
pidium iodide (Sigma-Aldrich Chemie BV) and 100 Kunitz
units RNAseA (Amersham Pharmacia Biotech, Essex,
UK) and incubated for 60 minutes at RT. Flow cytometric
analysis of nuclear DNA content was performed on a
FACSCalibur (BD Immunocytometry Systems, Erembo-
degem, Belgium).
Immunohistochemical Studies
Cytocentrifuge preparations were stained using the
rabbit-anti-mouse (RM) and APAAP method for the fol-
lowing mouse antibody clones: 5B5 (anti-prolyl 4-hydrox-
ylase (collagen synthesis)), E29 (anti-epithelial mem-
brane antigen), II-7 (anti-carcinoembryonic antigen),
HBME-1 (anti-mesothelial cell), Ber-EP4 (epithelial anti-
gen), RCK108 (anti-cytokeratin 19) (all antibodies were
obtained from DAKO, Glostrup, Denmark). Appropriate
positive controls were used in each case. Specificity of
the primary and secondary antibodies was checked by
using protein concentration and isotype-matched non-
relevant monoclonal antibodies and PBS. Naphtol-AS-
MX-phosphate (0.30 mg/ml, Sigma-Aldrich Chemie BV)
and new fuchsine (160 mg/ml in 2 mol/L HCl, Chroma-
Gesellschaft, Kongen, Germany) were used as substrate
for alkaline phosphatase (AP). Levamisol (0.25 mg/ml,
Sigma-Aldrich Chemie BV) was added to block endoge-
nous AP activity. Finally, sections were counter-stained
with Mayer’s hematoxylin (Merck, Darmstadt, Germany)
and mounted in Kaiser’s glycerol-gelatin (Merck).
Tumorigenicity in Vitro and in Immune-Deficient Mice
The tumorigenicity of cell lines was determined by their
capacity of forming colonies in semi-solid media.12 An
agarose underlay was prepared by adding 1 ml auto-
claved 0.8% (w/v) agarose (GIBCO/Invitrogen) in PBS to
a 6-well plate per well and allowed to gel for 30 minutes.
Cells were collected by trypsinization and adjusted to a
concentration of 5  104 cells per 3 ml RPMI 1640 me-
dium containing HEPES, Glutamax, gentamicin, and 10%
FBS. The cells were diluted in 3 ml StemPro 2.3% meth-
ylcellulose (GIBCO/Invitrogen), and the tube was vigor-
ously vortexed until the cells were uniformly suspended.
After 10 minutes of allowing the air bubbles to rise, the
suspension was added to the agarose underlay and in-
cubated in a humidified incubator at 37°C for 14 days or
until colonies were formed. The tumor-forming capacity of
the cell lines was also tested in athymic nude mice.
Monolayer cells were harvested by trypsinization, and
2  106 cells suspended in 0.2 ml of PBS were injected
subcutaneously into 4- to 6-week-old BALB/c athymic
nu/nu mice (Jackson Laboratory, Bar Harbor, ME). Mice
were maintained in sterile-air laminar flow cage racks and
examined regularly for tumor development for at least 2
months following the injection.
Virus Contamination, HLA Typing, and Karyotyping
Contamination of the cell lines with HCV, HBV, and HIV
viruses was analyzed with (quantitative) polymerase
chain reaction at the virology laboratory of the Erasmus
MC-Dijkzigt according to World Health Organization ref-
erences. The Department of Immunohematology and
Blood Transfusion of the Leiden University Medical Cen-
ter performed HLA typing. Karyotyping was carried out in
the Department of Clinical Genetics of the Erasmus MC.
Isolation of Mesothelioma-Derived Exosomes
Mesothelioma cell lines at 80% confluency were washed
twice with PBS and incubated in RPMI medium (contain-
ing HEPES, Glutamax, and gentamicin) and the serum
replacer TCH (1X working strength [ICN, Irvine, CA]) for
48 hours in a humidified atmosphere of 5% CO2, 95% air.
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Cell culture supernatants were subjected to three suc-
cessive centrifugations to remove cells and debris: 300
g for 10 minutes, 2000  g for 20 minutes, and finally at
10,000  g for 30 minutes, all at 4°C. Exosomes were
then pelleted at 64,000 g for 100 minutes using a SW28
rotor (Beckman Coulter Instruments, Fullerton, CA). Pel-
lets were resuspended and washed in PBS and centri-
fuged at 100,000  g for 1 hour (SW60 rotor, Beckman
Coulter Instruments). Exosomes were resuspended in
PBS, aliquoted, and stored at 80°C. The quantification
of exosomal proteins recovered was measured by
CBQCA kit according to the manufacturer’s recommen-
dations (Molecular Probes, Leiden, The Netherlands). In
the presence of cyanide, the ATTO-TAG CBQCA reagent
reacts with the primary amides found on proteins and
functions well in the presence of lipids and detergents.
The fluorescence emission was measured at 550 nm
(filter 530  30 nm) with excitation at 465 nm (filter
485  20 nm) in a CytoFluor 4000 fluorescence micro-
plate reader (gain 40) (PerSeptive Biosystems, Foster
City, CA).
Electron Microscopy
Exosomes obtained after centrifugation of cell-culture su-
pernatants were loaded onto Formvar carbon-coated
grids. Adsorbed exosomes were fixed in 2% paraformal-
dehyde and immunolabeled with CLB-gran1/2, 435 (anti-
CD63; CLB, Amsterdam, The Netherlands) and 10 nm
protein A gold particles.
Protein Electrophoresis
One-dimensional electrophoresis of mesothelioma-de-
rived exosomes onto 10% SDS-PAGE gels was per-
formed according to manufacturer’s recommendations
(PROTEAN II xi Cell, BioRad Laboratories, Hemel Hemp-
stead, UK). Samples were taken-up in 8 mol/L urea (Sig-
ma-Aldrich Chemie BV), 2% CHAPS (Amersham Pharma-
cia Biotech), 20 mmol/L dithiothreitol (DTT, Sigma-Aldrich
Chemie BV), 0.01% bromophenol blue (Sigma-Aldrich
Chemie BV), and transferred onto a 1.0-mm thick 10%
SDS-PAGE gel. A constant current of 7 mA per gel at
10°C was applied. After 16 hours, gels were stained with
Novex Colloidal blue staining kit according to the manu-
facturer’s instructions (Invitrogen).
Enzymatic Digestion of Protein Spots
Colloidal blue stained protein spots were excised manu-
ally with a plastic plunger and transferred onto a 96-well
low protein binding microtiter plate (Nunc A/S, Roskide,
Denmark). Each excised plug was washed with 100 l
milli-Q for 5 minutes with shaking (650 rpm, Eppendorf
Geratebau GmbH, Hamburg, Germany). Gel plugs were
de-stained with 0.4% (w/v) ammonium hydrogen carbon-
ate (Sigma-Aldrich Chemie BV), 30% acetonitrile in water
by incubating two times for 20 minutes at RT. After a short
wash with Milli-Q, gel spots were dried in a rotary evap-
orator (Savant, Farmingdale, NY) for 30 minutes. Protein
digestion was performed with the addition of 4 l of 100
g/ml sequencing grade-modified trypsin (Promega,
Madison, WI) to each gel piece. The plate was sealed with
an adhesive aluminum foil and incubated overnight at RT.
MALDI-TOF Analysis of Peptides
After the specific hydrolysis at the carboxylic sides of
lysine and arginine residues by trypsin, 7 l (1:2) aceto-
nitrile:0.1% trifluoroacetic acid was added to the gel
plugs. After mixing, 1 l of the tryptic digest was taken
and co-crystallized with 2.5 l 2 mg/ml of the photoactive
compound -cyano-4-hydroxy-trans-cinnamic acid (-
HCCA, Bruker Daltonics, Billerica, MA) in acetonitrile.
This sample-matrix solution (0.5 l) was pipetted onto a
400-m 384-well anchor chip MALDI-TOF plate and air-
dried for 5 minutes. Peptide mass spectra were acquired
on a Biflex III MALDI-TOF mass spectrometer equipped
with a 337-nm nitrogen laser (Bruker Daltonics, Bremen,
Germany). The instrument was calibrated with a peptide
calibration standard (Bruker Daltonics). Spectra were
compared using autolytic fragments from trypsin. A mass
list of peptides was obtained from each digest and sub-
mitted to Matrix Science Mascot UK software to identify
the proteins in the MSDB database of the NCBI. The
criteria for identification of proteins were determined as
follows: maximum allowed peptide mass error of 200
ppm, at least five matching peptide masses, molecular
weight of identified protein should match estimated val-
ues by comparing with marker proteins, and top scores
given by software higher than 61 (P  0.05).
Western Blotting
For Western blotting following one-dimensional SDS-
PAGE, proteins were electroblotted onto Immobilon P
membranes (Millipore Corp, Etten-Leur, The Nether-
lands) and incubated with specific antibodies, followed
by horseradish peroxidase-conjugated secondary anti-
bodies, and detected using SuperSignal West Pico
chemiluminescent substrate (Pierce Perbio Science, Et-
ten-Leur, The Netherlands). Antibodies used in this study
to confirm the proteins detected by MALDI-TOF were:
anti-HSC70 (clone 13D3; Affinity BioReagents, Golden,
CO), anti-HSP90 (clone AC88; Stressgen, Victoria, Can-
ada), anti-fascin (clone FCN01, Abcam Ltd, Cambridge,
UK), and anti--tubulin (clone E7, Developmental Studies
Hybridoma Bank, Iowa City, IA).
Results
Establishment and Characterization of Human
Mesothelioma Cell Lines
Since 1997, the Department of Pulmonary Medicine Rot-
terdam (PMR) has established 10 continuously growing
cell lines originally initiated from pleural effusions from pa-
tients diagnosed as malignant mesothelioma (MM). One
cell line was derived from a postmortem pleural biopsy. The
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10 patients from whom cell lines were derived were all
males ranging in age from 45 to 79 years (mean, 61 years).
Two mesothelioma cell lines, PMR-MM7 and PMR-MM8,
were characterized as summarized in Table 1.
Based on these characteristics and by judgment of the
Dutch mesothelioma expert panel these cell lines were
regarded as true mesothelioma and were differentiated
from pleural metastasis of adenocarcinoma. Furthermore,
the cells were free from bacterial and viral contaminants,
excluding the possibility of viral and bacterial proteins in
the exosome preparation.
Isolation and Characterization of Mesothelioma-
Derived Exosomes
Exosomes from seven mesothelioma cell lines were col-
lected from 80% confluent cultures after culturing for 48
hours in medium supplemented with a serum replacer.
Exosomes were purified by successive (ultra)-centrifuga-
tion steps. Initial experiments with medium containing
fetal bovine serum deprived of cells pelleted also protein
components from the serum. Medium containing the se-
rum replacer TCH gave no protein contamination in the
exosome preparation (data not shown). Typically, 15 to
50 g proteins were isolated from 25-ml culture medium
after 48 hours of incubation with an 80% confluent layer of
mesothelioma cells (175-cm2 flask). Protein content was
based on the CBQCA quantitation kit because it functions
well in the presence of lipids and can be used directly to
determine the amount of proteins in lipid-protein sam-
ples. Electron microscopically, the extracellular particles
isolated from the culture supernatant after removal of
cells by centrifugation consisted of membrane vesicles
as shown in Figure 1. Cellular debris was rarely found.
Figure 1. Electron micrograph of mesothelioma cell line PMR-MM7-derived
exosomes, showing cup-shaped membrane vesicles. Exosomes were fixed in
2% formaldehyde and immunolabeled for CD63 as described in the Materials
and Methods section (bar, 200 nm). Similar results were obtained with the
PMR-MM8-derived exosome preparation (not shown).
Figure 2. Separation of mesothelioma cell-derived exosomal proteins on
10% SDS-PAGE and stained by colloidal blue. Lanes A to G represent the
different mesothelioma cell lines, PMR-MM1, PMR-MM3, PMR-MM5, PMR-
MM7, PMR-MM8, PMR-MM9, and PMR-MM10, respectively.
Table 1. Characteristics of the Mesothelioma Cell Lines PMR-MM7 and PMR-MM8
PMR-MM7 PMR-MM8
Patient
Gender Male (Caucasian) Male (Caucasian)
Age 63 57
Cellular DNA content Aneuploid Diploid
Immunohistochemistry
5B5 Positive Positive
II-7 (CEA) Negative Negative
HBME-1 Negative Negative
Ber-EP4 Negative Negative
RCK108 Negative Positive
Tumorigenicity Yes Yes
Virus contamination HCV, HBV, HIV negative HCV, HBV, HIV negative
Bacterial contamination No No
Karyotyping 71783,XY,X,Y,del(1p),add (2p),
add(2p),?add(3q),del(5q),del(5q),
del(5q),der(6)t(6;7),der(6)t(6;7),del(7p),
7,7,add(8q),add(9p),add(9p),del(9p),
del(10p),11,11,der(12),t(2;12),add(13p),
14,15,add(17q),add(19q),20,add(20q),
21?,22?,mar1,mar2,mar3
4041,add(Xq),Y,add(1p),1,add(2q),
der(3)t(2;3),4,add(5q),?5,del(6p),
del(6q),inv(7),8,add(10p),del(10q),
del(11q),add(12q),13,13,der(14p)t
(14;15),der(15)t(8;15),der(16)t(14;16),
19,22?
HLA typing A*02,A*68,A*28,B*27,B*40,Bw*04,Bw*06,
Cw*0304,Cw*03Cw*0704,Cw*07
A*01,B*39,B*16,Bw*06,Cw*0501,Cw*05
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Proteomic Analysis
The protein composition of exosomes isolated from seven
different mesothelioma cell lines was determined by elec-
trophoretic separation onto a 10% SDS-PAGE gel (Figure
2). Because protein bands showed similar patterns be-
tween the different exosome preparations, two cell lines
were depicted to characterize all distinct bands by
MALDI-TOF mass spectrometry. Therefore, 50 g of exo-
somes derived from PMR-MM7 cells and PMR-MM8 cells
were loaded onto a 10% SDS-PAGE gel (Figure 3). All
distinct bands were subjected to MALDI-TOF analysis.
As mentioned in the Materials and Methods section, cri-
teria for positive protein identification were set as follows:
maximum allowed peptide mass error of 200 ppm, at
least five matching peptide masses, molecular weight of
identified protein should match estimated values, and top
score given by software. Results are presented in Table
2. The first column corresponds to the numbers on the
SDS-PAGE gel followed by a description from which cell
lines the exosomes were derived. Protein names, acces-
sion numbers, and calculated molecular weights were
deduced from the mass fingerprint analysis in the MSDB
database of the NCBI. Observed molecular weights were
measured by interpolation by image analysis software
with the molecular weight curve obtained from the mo-
lecular weight marker proteins run as a separate track on
the gel. SDS-PAGE allows only an estimation of the mass
of a protein. Differences between the calculated molec-
ular weight and observed molecular weight can be
caused by excessive post-translational modifications,
which were not predicted in the theoretical digestion of
the proteins in the database as well as precluding pep-
tides from the fingerprint. The last column corresponds to
the score given by the Matrix Science Mascot UK soft-
ware analysis, which was significant (P  0.05) when
higher than 61.
Analysis of the exosomes by Western blot (Figure 4)
confirmed the presence of the proteins detected by
MALDI-TOF mass spectrometry. Antibodies against fas-
cin, -tubulin, HSC70, and HSP90 could be visualized by
Western blot. As an illustration that some proteins were
still present in both cell lines, even when only one gave a
statistically significant result using our strict criteria for the
MALDI-TOF technique, HSP70, fascin, and -tubulin pro-
teins were detected in one cell line by MALDI-TOF,
whereas they were demonstrated in both cell lines using
Western blotting.
Discussion
Tumor exosomes are poorly defined. In contrast to den-
dritic cell-derived exosomes, no studies have described
an extensive protein characterization of tumor exosomes.
Initial exosome isolations from pleural effusion turned out
to be troublesome, caused by high amounts of immuno-
globulins and complement factors present in the fluid.13
Exosomes in pleural effusions will not only be secreted by
mesothelioma cells, but also by mesothelial cells or from
cells of hematopoietic origin present in the fluid. Therefore,
mesothelioma cell line-derived exosomes were studied for
their protein content. The seven mesothelioma cell lines
described in this study secrete exosomes into their envi-
ronment. Exosome-like vesicles were isolated from the
culture supernatant after 48 hours of secretion by the cell
lines through successive centrifugation steps. Electron
microscopy showed 60 to 150 nm diameter vesicles.
After one-dimensional electrophoresis of these exosome
preparations, protein spots from two mesothelioma cell
lines were analyzed by MALDI-TOF mass spectrometry.
Earlier studies showed that exosomes derived from
mouse tumors concentrate tumor antigens and contain
MHC class I molecules loaded with tumor peptides.6
Similarly, MHC class I was found to be present on human
tumor-derived exosomes that may be involved in the
presentation of polypeptide fragments of antigens to T
cells. Heat shock proteins (HSP) are a group of common
proteins that play a role in the cell’s response to elevated
Figure 3. Exosomes derived from the mesothelioma cell lines PMR-MM7 (B)
and PMR-MM8 (C) after electrophoresis in a denaturing polyacrylamide gel
(A, broad range marker in kilodaltons (kd)). Numbers correspond to the
excised protein bands (see Table 2)
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temperature, infection, cytokine stimulation, metabolic
starvation, and other environmental stresses. Indicated
by intense bands on the PAGE-gel, high amounts of
HSP90 and heat shock cognate protein (HSC) 70 were
present in mesothelioma-derived exosomes. HSP are
normally present in small amounts within the cytoplasm of
all cells in all life forms but can also be released into the
extracellular environment in the absence of cellular ne-
crosis.14 The precise mechanisms by which HSP are
actively released by viable cells have not yet been elu-
cidated but we propose that exosomes may play a role in
releasing HSP from cells. Inside cells, HSP play a role in
protein trafficking, whereby they fold other proteins prop-
erly, keep them in correct and functional shape, or trans-
port them from one location to another.15 They act thus as
chaperones, bringing along with them small fragments,
or peptides, derived from other proteins expressed in that
cell, providing a “fingerprint” of the cell’s content.16
Therefore, exosomes carrying high amounts of HSP from
a patient’s tumor may be good candidates for a cancer
immune therapy without the need to identify what those
antigens are. HSP in exosomes can be taken up by
dendritic cells and macrophages (perhaps by CD91 re-
ceptor-mediated endocytosis17–19), and processed for
presentation to the immune system in the lymph nodes.
The tumor-specific antigens are released from the HSP
inside the cell and presented to cytotoxic T cells (CTL), or
“killer cells,” which are then activated. Different studies
showed that immune cells stimulated with heat shock
proteins can eliminate different kinds of cancers,20–26
Table 2. Identified Exosomal Proteins Secreted by Mesothelioma Cells (Ordered by Observed Molecular Weight)
No.
PMR
MM Protein
Accession
number
Calculated
mol wt
Observed
mr Peptides Coverage
Top
score*
1 8 desmoplakin I A38194 309.797 272 36 11% 116
2 8 fibronectin precursor CAA26536 256.529 228 31 15% 148
3 8 myosin CAB05105 226.392 205 29 13% 97
4 8 putative P150 O00378 148.786 174 15 10% 72
5 7 integrin alpha-3 chain precursor A40021 116.538 136 15 17% 69
6 8 hypothetical protein fragment Q9HAj5 71.444 115 17 15% 87
7 8 epithelial microtubule-associated protein I37356 84.002 115 16 13% 68
8 7 actinin-4 BAA24447 102.204 106 12 11% 67
9 7 heat shock protein 90-alpha HS9A_HUMAN 84.490 95 8 21% 112
10 8 heat shock protein 90 AAA36026 83.212 93 24 27% 197
11 7 ezrin Q96CU8 69.370 84 16 25% 134
12 8 ezrin EZRI_HUMAN 69.225 81 14 20% 125
13 7 moesin MOES_HUMAN 67.647 79 9 13% 75
14 7 albumin 1A06A 65.695 74 15 14% 107
15 7 annexin VI ANX6_HUMAN 75.695 74 14 16% 75
16 8 moesin MOES_HUMAN 67.647 73 17 24% 161
17 8 heat shock cognate protein 70 A27077 70.854 70 12 17% 85
18 7 pyruvate kinase KPY1_HUMAN 57.710 63 7 9% 87
19 8 integrin-binding protein DEL1 precursor O43854 53.730 60 12 20% 102
20 7 beta-tubulin I38369 48.848 60 7 13% 71
21 8 fascin FSC1_HUMAN 54.365 60 8 15% 72
22 8 kinesin-like protein 2 Q9NS87 160.061 57 12 7% 70
23 7 enolase alpha ENOA_HUMAN 47.008 52 8 17% 65
24 8 PV1 protein Q9BX97 50.562 50 8 16% 65
25 8 protein kinase A38643 53.676 50 11 21% 62
26 8 translation initiation factor FIMS4A 46.125 50 12 31% 77
27 7 actin AAH08633 40.978 49 12 29% 111
28 8 actin AAH08633 40.978 47 12 36% 126
29 8 23-cyclic-nucleotide 3-phosphodiesterase BAA02435 45.070 45 11 28% 115
30 8 MHC class I HLA-B I68774 31.669 45 9 39% 103
31 8 MHC class I antigen (fragment) Q9TP25 21.011 45 8 44% 67
32 7 glyceraldehyde 3-phosphate dehydrogenase CAA25833 36.031 41 8 23% 89
33 8 glyceraldehyde 3-phosphate dehydrogenase G3P2_HUMAN 35.899 39 7 14% 75
34 8 annexin I 1AIN 35.018 39 8 24% 92
35 7 annexin II ANX2_HUMAN 38.449 39 21 52% 251
36 8 annexin II ANX2_HUMAN 38.449 37 13 31% 139
37 7 annexin V 1HVE 35.068 36 9 26% 88
38 8 annexin V 1HVE 35.068 35 7 22% 64
*Top scores higher than 61 were significant (p  0.05).
Figure 4. The presence of fascin (I), -tubulin (II), HSC70 (III), and HSP90
(IV) were confirmed by Western blots of PMR-MM7-derived exosomes (A)
and PMR-MM8-derived exosomes (B). The primary antibodies anti-fascin
(1:1000), anti--tubulin (1:10.000), and anti-HSP90 (1:2000) were followed
by horseradish peroxidase-conjugated goat anti-mouse IgG1. Anti-HSC70
(1:1000) was followed by Envision (DAKO). Blots were incubated with
SuperSignal West Pico chemiluminescent substrate and exposed to Hyper-
film ECL (Amersham Biosciences, Buckinghamshire, England).
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and phase III trails are underway in renal cancer and
metastatic melanoma. HSC70 has furthermore been de-
scribed as an important factor in the release of exosomes
during reticulocyte maturation27 and HSP73, present in
dendritic cell-derived exosomes, induced antitumor im-
mune responses in vivo.4
Annexins comprise a structurally conserved family of
proteins capable of binding in a Ca2-dependent man-
ner to phospholipids.28 Annexins participate in the regu-
lation of membrane organization, membrane traffic, and
the regulation of calcium currents across cell membranes
or within cells.29 After being exported outside of cells,
some annexins have been shown to function as receptors
for extracellular proteins and proteases and can interact
with glycoconjugates.30 Annexin A2 and annexin A6 par-
ticipate in disconnecting the clathrin lattice from the
spectrin membrane cytoskeleton during the final stages
of coated pit budding.31–33
The annexins found in this study (annexin A1 (syn-
onyms: annexin I/lipocortin 1)), annexin A2 (annexin II/
calpactin 1), annexin A5 (annexin V), and annexin A6
(annexin VI)) may regulate membrane-cytoskeleton dy-
namics and besides being involved in membrane-fusion
events between intracellular compartments, they play a
role in the inward vesiculation process.34
We and others could not detect tetraspanin molecules
by mass spectrometry techniques.35,36 However, immu-
nogold electron microscopy using an anti-CD63 (specific
tetraspanin marker of late endosomes) antibody showed
the presence of this protein at the exosome surface sug-
gesting it was under the threshold of detection of the
SDS-PAGE/MALDI-TOF technique.
Plasmalemma vesicle-associated protein (PLVAP) or
PV-1 is a caveolae-specific glycoprotein associated with
stomatal diaphragms of caveolae, transendothelial chan-
nels, and fenestrae and is highly conserved across spe-
cies.37 While for the diaphragms of fenestrae a “sieving”
function of the blood plasma components has been doc-
umented,38 there is no data documenting the function of
diaphragms of caveolae. PV-1 is anchored in the mem-
brane and could participate in protein-protein interac-
tions via the proline-rich region at the C terminus.38 Re-
sults of strong affinity between PV-1 and heparin
suggests that PV-1 may interact with heparan sulfate
proteoglycans located on cell surfaces or in the extracel-
lular matrix.39 Although data of PV-1 expression on me-
sothelial cells are lacking, PV-1 is expressed in many
types of multiple endocrine and endothelial cell types.39
Our data provide evidence for the presence of PV-1
protein in exosomes from mesothelioma cell lines but the
role of this protein both in exosomes and normal me-
sothelial cells is a matter under current investigation.
Cytoskeleton proteins as actin and tubulin give struc-
ture to the exosome together with the associated proteins
ezrin, moesin, actinin-4, desmoplakin I, and fascin. Ezrin
and moesin belong to the ERM family that attach actin
filaments to transmembrane glycoproteins and thereby
stabilize cell-surface protrusions.40–42 -actinin is a mi-
crofilament bundling and cross-linking protein that is
ubiquitously expressed in numerous actin structures of
virtually all cells. Four different isoforms encoding -ac-
tinin have been identified in humans. -actinin-1 exists as
a non-muscle or a smooth muscle isoform, -actinin-2
and -3 are skeleton muscle isoforms, and -actinin-4 is a
non-muscle isoform.43–46 Although both are non-muscle
isoforms, -actinin-4 exerts contradictory functions from
those of -actinin-1 with respect to their involvement in
cell movement. -actinin-4 is described to be associated
with enhanced cell motility and cancer invasion, espe-
cially in patients with a cytoplasmic localization of this
protein.46 After disassembly of the actin skeleton, -ac-
tinin-4 may reorganize the cytoskeleton by cross-linking
actin filaments, a process supposedly requisite for exo-
some formation. Recently, mutations in the ACTN4 gene,
which codes for -actinin-4, were reported to cause fa-
milial focal segmental glomerulosclerosis.47 Although
rarely detected in lung tumors, a point-mutation (adenine
3 thymine) in the ACTN4 gene of a non-small cell lung
cancer (NSCLC) cell line resulting in an asparagine in-
stead of lysine in actinin-4, leading to the expression of a
tumor-specific antigen recognized by autologous cyto-
toxic T lymphocytes (CTL).48–50 Preliminary data suggest
that the mesothelioma cell line (PMR-MM7, HLA-A02, A68)
is not recognized by the mutated actinin-4-specific CTL
clone (HLA-A02, A68, under current investigation (F. Mami-
Chouaib, Institut Gustave Roussy, Villejuif, France)).
Like actinin-4, fascin organizes actin filaments into
bundles and is predominantly present in dendrites, mi-
crospikes, microvilli, filopodia, and pseudopodia (or
called lamellipodia depending on the morphology) at the
cell periphery and in stress fibers in some cells. The
expression of fascin is described in cells that have the
morphological characteristic of membrane protrusions in
common, like glial and neuronal cells, microcapillary en-
dothelial cells, and antigen-presenting dendritic cells.
Therefore, it is suggested that fascin plays a role in
extending the membrane either for cell motility or for
interactions with other cell types. Fascin expression is
dramatically increased during maturation of DC.51 On
maturation of DC and their travel to lymph nodes to
present the antigen to T cells, numerous fascin-contain-
ing membrane extensions appear. At this stage, the se-
cretion of exosomes by DC is increased.9 High levels of
fascin is also observed in many cancer cells and appears
to be correlated with aggressive cell behavior.52,53 We
suggest that fascin may also be involved in the inward
budding of multi-vesicular bodies, which creates internal
vesicles that after fusion with the plasma membrane
leads to release of exosomes into the extracellular milieu.
Desmoplakin is required for assembly of functional
desmosomes (a type of junction that attaches one cell to
its neighbor) during epithelial sheet formation, maintain-
ing cytoskeletal architecture, and reinforcing membrane
attachments essential for stable intercellular adhesion.54
This intracellular anchor protein is responsible for con-
necting the cytoskeleton to transmembrane adhesion
proteins.
Molecular motor proteins mediate the intracellular
transport of membrane-enclosed organelles. Kinesin-like
protein, a microtubule-based motor protein, was found.
The membrane orientation of exosomes is identical to
that of cells, during their formation cytoplasm is included
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into the vesicle. The metabolic enzymes, glyceraldehyde
3-phosphate dehydrogenase, enolase-1, and pyruvate
kinase, are involved in the glycolysis. This process in
which glucose is converted into pyruvate with the concom-
itant production of ATP occurs in the cytosol. Regulation of
the production of cyclic AMP is done by 23-cyclic-nucle-
otide 3 phosphodiesterase. The phenomenon of increased
expression of glucose transporters and glycolytic en-
zymes in tumor cells was described as the Warburg
effect55 and is one of the most universal characteristics of
solid tumors.56–58 The genes of these products are also
found to be up-regulated in expression mapping in me-
sothelioma oncogenesis (Singhal S, personal communi-
cation). High amounts of glycolytic enzymes in the cyto-
plasm of cells will thus be reflected by the presence of
these enzymes in exosomes. There are no data pub-
lished on the distribution and function of the putative
P150 protein (code O00378).
Some of the proteins present in mesothelioma-derived
exosomes like MHC class I, HSC70, HSP90, annexins
(A1, A2, A5, A6), actin, and tubulin were also described
to be present in B cell-derived exosomes35 and dendritic
cell-derived exosomes.5 Furthermore, proteomic analysis
of B cell-derived exosomes revealed the presence of
moesin, glyceraldehyde 3-phosphate dehydrogenase,
pyruvate kinase, and enolase in common with our results
on mesothelioma-derived exosomes.35 Common proteins
with intestinal epithelial cell exosomes are MHC class I,
actin, tubulin, and enolase-1 and with other tumor-de-
rived exosomes are MHC class I and HSC70.59
Most interesting was the detection of a protein, not
described previously on exosomes, a precursor of the
developmental endothelial locus-1 (DEL-1) protein.
DEL-1 has structural homology to lactadherin and has a
regulatory function in vascular remodeling during embryo
genesis.60 It is described as an extracellular matrix pro-
tein that promotes adhesion of endothelial cells via the
v3 integrin receptor present on endothelial cells. The
v3 integrin receptor is also present on dendritic cells
and mediates the uptake of apoptotic vesicles, important
for cross priming of tumor antigens. It is speculative that
DEL-1 on tumor-exosomes is important for targeting exo-
somes to DC for cross-presentation. Recently, Aoka et
al61,62 suggested that DEL-1 acts as an angiogenic factor
in the context of solid tumor formation and that the in-
crease in vascular development accelerates tumor
growth through decreased apoptosis. The role of DEL-1
in tumor exosomes can be bilateral first, attachment to
dendritic cells and secondly, to increase the vascular
development in the neighborhood of the tumor. Exo-
somes may also bind to extracellular matrix components
by fibronectin, a ligand for integrins.
Proteomic analysis using MALDI-TOF mass spectrom-
etry revealed several new proteins not previously de-
scribed on (tumor) exosomes or for mesothelioma cell
lines. In conclusion, mesothelioma cell line-derived exo-
somes express a discrete set of proteins involved in
antigen presentation, signal transduction, migration, and
adhesion and thereby may be an important pathway in
the communication between cells.
Acknowledgments
We thank Hans Dalebout, Lies-Anne Severijnen, and Jan-
ice Griffith for their assistance in the MALDI-TOF mass
spectrometry studies and electron microscopy studies,
respectively. We also thank the Department of Clinical
Genetics of the Erasmus MC for karyotyping the me-
sothelioma cell lines.
References
1. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV,
Melief CJ, Geuze HJ: B lymphocytes secrete antigen-presenting ves-
icles. J Exp Med 1996, 183:1161–1172
2. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ:
Exosome: from internal vesicle of the multi-vesicular body to intercel-
lular signaling device. J Cell Sci 2000, 113:3365–3374
3. Thery C, Zitvogel L, Amigorena S: Exosomes: composition, biogene-
sis, and function. Nat Rev Immunol 2002, 2:569–579
4. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Cast-
agnoli P, Raposo G, Amigorena S: Molecular characterization of
dendritic cell-derived exosomes: selective accumulation of the heat
shock protein hsc73. J Cell Biol 1999, 147:599–610
5. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G,
Garin J, Amigorena S: Proteomic analysis of dendritic cell-derived
exosomes: a secreted subcellular compartment distinct from apopto-
tic vesicles. J Immunol 2001, 166:7309–7318
6. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C,
Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S,
Zitvogel L: Tumor-derived exosomes are a source of shared tumor
rejection antigens for CTL cross-priming. Nat Med 2001, 7:297–303
7. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P,
Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena
S, Raposo G, Angevin E, Zitvogel L: Malignant effusions and immu-
nogenic tumour-derived exosomes. Lancet 2002, 360:295–305
8. Amigorena S: Anti-tumour immunotherapy using dendritic cell-de-
rived exosomes. Res Immunol 1998, 149:661–662
9. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D,
Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of es-
tablished murine tumors using a novel cell-free vaccine: dendritic
cell-derived exosomes. Nat Med 1998, 4:594–600
10. Zitvogel L, Fernandez N, Lozier A, Wolfers J, Regnault A, Raposo G,
Amigorena S: Dendritic cells or their exosomes are effective biothera-
pies of cancer. Eur J Cancer 1999, 35:S36–S38
11. Hoogsteden HC, Langerak AW, van der Kwast TH, Versnel MA, van
Gelder T: Malignant pleural mesothelioma. Crit Rev Oncol Hematol
1997, 25:97–126
12. Freedman VH, Shin SI: Cellular tumorigenicity in nude mice: correla-
tion with cell growth in semi-solid medium. Cell 1974, 3:355–359
13. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R,
Severijnen LA, Van Meerbeeck JP, Burgers SA, Hoogsteden HC,
Lambrecht BN: Proteomic analysis of exosomes isolated from human
malignant pleural effusions. Am J Respir Cell Mol Biol, 2004, Feb 19
[Epub ahead of print]
14. Pockley AG: Heat shock proteins in health and disease: therapeutic
targets or therapeutic agents? Exp Rev Mol Med 2001. Sept 21:1–21
15. Gething MJ, Sambrook J: Protein folding in the cell. Nature 1992,
355:33–45
16. Young D, Roman E, Moreno C, O’Brien R, Born W: Molecular chap-
erones and the immune response. Philose Trans R Soc Lond B Biol
Sci 1993, 339:363–367; 367–368
17. Arnold-Schild D, Hanau D, Spehner D, Schmid C, Rammensee HG,
de la Salle H, Schild H: Cutting edge: receptor-mediated endocytosis
of heat shock proteins by professional antigen-presenting cells. J Im-
munol 1999, 162:3757–3760
18. Binder RJ, Han DK, Srivastava PK: CD91: a receptor for heat shock
protein gp96. Nat Immunol 2000, 1:151–155
19. Basu S, Binder RJ, Ramalingam T, Srivastava PK: CD91 is a common
receptor for heat shock proteins gp96, hsp90, hsp70, and calreticu-
lin. Immunity 2001, 14:303–313
20. Udono H, Srivastava PK: Comparison of tumor-specific immunoge-
1814 Hegmans et al
AJP May 2004, Vol. 164, No. 5
nicities of stress-induced proteins gp96, hsp90, and hsp70. J Immu-
nol 1994, 152:5398–5403
21. Basu S, Srivastava PK: Calreticulin, a peptide-binding chaperone of
the endoplasmic reticulum, elicits tumor- and peptide-specific immu-
nity. J Exp Med 1999, 189:797–802
22. Wang XY, Kazim L, Repasky EA, Subjeck JR: Characterization of heat
shock protein 110 and glucose-regulated protein 170 as cancer
vaccines and the effect of fever-range hyperthermia on vaccine ac-
tivity. J Immunol 2001, 166:490–497
23. Robert J, Menoret A, Basu S, Cohen N, Srivastava PR: Phylogenetic
conservation of the molecular and immunological properties of the
chaperones gp96 and hsp70. Eur J Immunol 2001, 31:186–195
24. Srivastava PK, Maki RG: Stress-induced proteins in immune response
to cancer. Curr Top Microbiol Immunol 1991, 167:109–123
25. Goldman B: Cancer vaccines: finding the best way to train the im-
mune system. J Natl Cancer Inst 2002, 94:1523–1526
26. Srivastava PK: Purification of heat shock protein-peptide complexes
for use in vaccination against cancers and intracellular pathogens.
Methods 1997, 12:165–171
27. Geminard C, Nault F, Johnstone RM, Vidal M: Characteristics of the
interaction between Hsc70 and the transferrin receptor in exosomes
released during reticulocyte maturation. J Biol Chem 2001, 276:
9910–9916
28. Creutz CE: The annexins and exocytosis. Science 1992, 258:924–
931
29. Gerke V, Moss SE: Annexins: from structure to function. Physiol Rev
2002, 82:331–371
30. Raynal P, Pollard HB: Annexins: the problem of assessing the bio-
logical role for a gene family of multifunctional calcium- and phos-
pholipid-binding proteins. Biochim Biophys Acta 1994, 1197:63–93
31. Gerke V, Weber K: Identity of p36K phosphorylated upon Rous sar-
coma virus transformation with a protein purified from brush borders:
calcium-dependent binding to non-erythroid spectrin and F-actin.
EMBO J 1984, 3:227–233
32. Kamal A, Ying Y, Anderson RG: Annexin VI-mediated loss of spectrin
during coated pit budding is coupled to delivery of LDL to lysosomes.
J Cell Biol 1998, 142:937–947
33. Turpin E, Russo-Marie F, Dubois T, de Paillerets C, Alfsen A, Bomsel
M: In adrenocortical tissue, annexins II and VI are attached to clath-
rin-coated vesicles in a calcium-independent manner. Biochim Bio-
phys Acta 1998, 1402:115–130
34. Futter CE, Felder S, Schlessinger J, Ullrich A, Hopkins CR: Annexin I
is phosphorylated in the multi-vesicular body during the processing
of the epidermal growth factor receptor. J Cell Biol 1993, 120:77–83
35. Wubbolts RW, Leckie RS, Veenhuizen PT, Schwartzmann G, Moebius
W, Hoernschemeyer J, Slot JW, Geuze HJ, Stoorvogel W: Proteomic
and biochemical analyses of human B cell-derived exosomes: poten-
tial implications for their function and multi-vesicular body formation.
J Biol Chem 2003, 278:10963–10972
36. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze
HJ: Selective enrichment of tetraspan proteins on the internal vesicles
of multi-vesicular endosomes and on exosomes secreted by human
B-lymphocytes. J Biol Chem 1998, 273:20121–20127
37. Stan RV, Arden KC, Palade GE: cDNA and protein sequence,
genomic organization, and analysis of cis regulatory elements of
mouse and human PLVAP genes. Genomics 2001, 72:304–313
38. Stan RV, Kubitza M, Palade GE: PV-1 is a component of the fenestral
and stomatal diaphragms in fenestrated endothelia. Proc Natl Acad
Sci USA 1999, 96:13203–13207
39. Hnasko R, McFarland M, Ben-Jonathan N: Distribution and charac-
terization of plasmalemma vesicle protein-1 in rat endocrine glands.
J Endocrinol 2002, 175:649–661
40. Tsukita S, Yonemura S: ERM (ezrin/radixin/moesin) family: from cy-
toskeleton to signal transduction. Curr Opin Cell Biol 1997, 9:70–75
41. Tsukita S, Yonemura S: ERM proteins: head-to-tail regulation of actin-
plasma membrane interaction. Trends Biochem Sci 1997, 22:53–58
42. Shaw RJ, Henry M, Solomon F, Jacks T: RhoA-dependent phosphor-
ylation and relocalization of ERM proteins into apical membrane/actin
protrusions in fibroblasts. Mol Biol Cell 1998, 9:403–419
43. Beggs AH, Byers TJ, Knoll JH, Boyce FM, Bruns GA, Kunkel LM:
Cloning and characterization of two human skeletal muscle -actinin
genes located on chromosomes 1 and 11. J Biol Chem 1992, 267:
9281–9288
44. Millake DB, Blanchard AD, Patel B, Critchley DR: The cDNA se-
quence of a human placental -actinin. Nucleic Acids Res 1989,
17:6725
45. Youssoufian H, McAfee M, Kwiatkowski DJ: Cloning and chromo-
somal localization of the human cytoskeletal -actinin gene reveals
linkage to the -spectrin gene. Am J Hum Genet 1990, 47:62–71
46. Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, Yamada Y,
Chiba H, Hirohashi S: Actinin-4, a novel actin-bundling protein asso-
ciated with cell motility and cancer invasion. J Cell Biol 1998, 140:
1383–1393
47. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ,
Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR:
Mutations in ACTN4, encoding -actinin-4, cause familial focal seg-
mental glomerulosclerosis. Nat Genet 2000, 24:251–256
48. Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V,
Chouaib S, Coulie PG: A point mutation in the -actinin-4 gene gener-
ates an antigenic peptide recognized by autologous cytolytic T lympho-
cytes on a human lung carcinoma. Cancer Res 2001, 61:4078–4083
49. Echchakir H, Dorothee G, Vergnon I, Menez J, Chouaib S, Mami-
Chouaib F: Cytotoxic T lymphocytes directed against a tumor-spe-
cific mutated antigen display similar HLA tetramer binding but distinct
functional avidity and tissue distribution. Proc Natl Acad Sci USA
2002, 99:9358–9363
50. Mami-Chouaib F, Echchakir H, Dorothee G, Vergnon I, Chouaib S:
Antitumor cytotoxic T-lymphocyte response in human lung
carcinoma: identification of a tumor-associated antigen. Immunol Rev
2002, 188:114–121
51. Pinkus GS, Pinkus JL, Langhoff E, Matsumura F, Yamashiro S, Mo-
sialos G, Said JW: Fascin, a sensitive new marker for Reed-Sternberg
cells of Hodgkin’s disease: evidence for a dendritic or B cell deriva-
tion? Am J Pathol 1997, 150:543–562
52. Grothey A, Hashizume R, Sahin AA, McCrea PD: Fascin, an actin-
bundling protein associated with cell motility, is up-regulated in hormone
receptor-negative breast cancer. Br J Cancer 2000, 83:870–873
53. Grothey A, Hashizume R, Ji H, Tubb BE, Patrick Jr CW, Yu D, Mooney
EE, McCrea PD: C-erbB-2/ HER-2 up-regulates fascin, an actin-
bundling protein associated with cell motility, in human breast cancer
cell lines. Oncogene 2000, 19:4864–4875
54. Vasioukhin V, Bowers E, Bauer C, Degenstein L, Fuchs E: Desmo-
plakin is essential in epidermal sheet formation. Nat Cell Biol 2001,
3:1076–1085
55. Warburg O: On the origin of cancer cells. Science 1956, 123:309–314
56. Galarraga J, Loreck DJ, Graham JF, DeLaPaz RL, Smith BH, Hallgren
D, Cummins CJ: Glucose metabolism in human gliomas: correspon-
dence of in situ and in vitro metabolic rates and altered energy
metabolism. Metab Brain Dis 1986, 1:279–291
57. Dang CV, Semenza GL: Oncogenic alterations of metabolism. Trends
Biochem Sci 1999, 24:68–72
58. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laugh-
ner E, Ravi R, Simons J, Taghavi P, Zhong H: “The metabolism of tumours”:
70 years later. Novartis Found Symp 2001, 240:251–260; 260–254
59. van Niel G, Heyman M: The epithelial cell cytoskeleton and intracel-
lular trafficking. II. Intestinal epithelial cell exosomes: perspectives on
their structure and function. Am J Physiol 2002, 283:G251–G255
60. Hidai C, Zupancic T, Penta K, Mikhail A, Kawana M, Quertermous EE,
Aoka Y, Fukagawa M, Matsui Y, Platika D, Auerbach R, Hogan BL,
Snodgrass R, Quertermous T: Cloning and characterization of devel-
opmental endothelial locus-1: an embryonic endothelial cell protein
that binds the v3 integrin receptor. Genes Dev 1998, 12:21–33
61. Aoka Y, Johnson FL, Penta K, Hirata Ki K, Hidai C, Schatzman R,
Varner JA, Quertermous T: The embryonic angiogenic factor Del1
accelerates tumor growth by enhancing vascular formation. Micro-
vasc Res 2002, 64:148–161
62. Zhong J, Eliceiri B, Stupack D, Penta K, Sakamoto G, Quertermous T,
Coleman M, Boudreau N, Varner JA: Neovascularization of ischemic
tissues by gene delivery of the extracellular matrix protein Del-1.
J Clin Invest 2003, 112:30–41
Proteomics of Mesothelioma-Derived Exosomes 1815
AJP May 2004, Vol. 164, No. 5
